Specialty chemicals & pharma company incorporated a new subsidiary for business expansion!
Specialty chemicals & pharma company incorporated a new subsidiary for business expansion!
The stock gave multibagger returns of over 200 per cent from its 52-week low of Rs 58.20 per share.
The stock gave multibagger returns of over 200 per cent from its 52-week low of Rs 58.20 per share.
Mukul Agrawal and Vijay Kedia Gains Rs 6.71 Crore and Rs 19.19 Crore as Stock Hits Upper Circuit Today: Stock Rallies Over 900 Per cent in Just 2 Years!
The company’s shares have delivered a multibagger return of over 200 per cent in the past 1 year.
The company’s shares have delivered a multibagger return of over 200 per cent in the past 1 year.
3:1 Bonus Share & FIIs took a fresh entry in this low PE, high ROE & high ROCE multibagger pharma stock under Rs 80; PAT zooms over 500 per cent
The stock gave multibagger returns of 1,460 per cent in 2 years, 2,300 per cent in 3 years and a whopping 14,200 per cent in 5 years.
The stock gave multibagger returns of 1,460 per cent in 2 years, 2,300 per cent in 3 years and a whopping 14,200 per cent in 5 years.
Penny Stock Under Rs 5: Don't Miss Out on the Micro-Cap's Major News!
This groundbreaking technology has the potential for eliminating the need for painful injections.
Transgene Biotek Ltd.'s partnership with NiedlFree Technologies has the potential to revolutionize the way people with diabetes manage their condition. Oral insulin delivery could eliminate the need for painful injections and make it easier for people to adhere to their treatment plans. This could lead to improved health outcomes and a better quality of life for millions of people worldwide.
Is The Pharmaceutical Industry Shaping Up To Be The New IT?
US Drug Shortages and India’s Competitive Advantage
Given the shared traits between the pharmaceutical and IT industries,
Special Feature On Pharmaceutical & Healthcare Industry
Keeping Good Health
The corona virus pandemic drew everyone's attention to the need for basic medical facilities across the country, elevating the pharmaceutical and healthcare industries and compelling the government to pay greater attention to them. Mandar Wagh describes how being a major participant in terms of both volume and value globally, the government's emphasis and initiatives all contribute to the success of the industry
Stock in focus: Pharma company hits milestone with successful Phase I study of DRL_TC a tocilizumab biosimilar; get full story here!
The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over the counter medications.
The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over-the-counter medications. With a history of scientific advancements and industry-first achievements, the company remains committed to investing in future business opportunities.
Multibaggers of 2022: These pharmaceutical stocks more than doubled the wealth of investors! Do you own them?
After a prolonged correction, the index underwent another surge in recent times as healthcare stocks gained momentum due to the deteriorating Covid scenario.
After a prolonged correction, the index underwent another surge in recent times as healthcare stocks gained momentum due to the deteriorating Covid scenario.
Advent International buys more than 50 per cent stake for Rs 6300 crore in this pharma company. Do you own it?
Advent is expected to buy 51 per cent of the promoter’s stake in the company and launch an open offer for an additional 26 per cent
The company released a press release on Monday, stating Advent International has entered into definitive agreement to acquire significant stake in the company and intends to explore the merger of its portfolio company
Stocks below Rs 100: Only buyers seen in these scrips on October 3
The FIIs sold equity worth Rs 1,565.31 crore on Friday (September 30) while the DIIs bought equity for a net worth of Rs 3,245.45 crore.
At the time of market closing on Monday, the headline equity indices, i.e. Sensex and Nifty 50 plunged over a per cent each, owing to the rising inflation fears in the US markets.
Stocks below Rs 100: Only buyers seen in these scrips on September 23
The FIIs sold equity worth Rs 2,409.55 crore on Thursday (September 22) while the DIIs bought equity for a net worth of Rs 263.07 crore
At 11.30 am on Friday, the headline equity indices, i.e. Sensex and Nifty 50 are seen extending their losing streak in the morning, owing to weak global cues.
Top-performing pharma stocks in July 2022
The pharmaceutical sector in India ranks third in terms of volume and fourteenth in terms of value (both globally).
The pharmaceutical sector in India ranks third in terms of volume and fourteenth in terms of value (both globally). The domestic market is anticipated to increase three times in the next ten years, according to the Indian Economic Survey 2021.